AstraZeneca
Executive Summary
AstraZeneca is a major UK-based multinational pharmaceutical company with significant global operations and a strong pipeline across oncology, cardiovascular, respiratory, and immunology. The company has extensive China operations through AstraZeneca China but maintains clear BIOSECURE status with no regulatory restrictions. AstraZeneca is highly active in licensing deals and partnerships, making it an attractive but competitive BD target requiring senior-level engagement.
Structure: AstraZeneca operates as a UK public company with direct subsidiary operations globally, including significant manufacturing and R&D presence in China through wholly-owned entities. The corporate structure is straightforward without VIE complications, though China operations require monitoring for potential future BIOSECURE implications.
Ownership & Shareholder Structure
BeiGene → AstraZeneca
AstraZeneca invested $1B in BeiGene for 20% stake (2020). Strategic oncology collaboration including tislelizumab ex-China development.
Hansoh Pharmaceutical → AstraZeneca
Hansoh oral GLP-1/GIP dual agonist competes in AZ metabolic franchise.
Tigermed → AstraZeneca
Tigermed provides clinical trial management services to AstraZeneca in China.
Alphamab Oncology → AstraZeneca
Alphamab envafolimab (PD-L1 single-domain antibody) partnership with AZ for subcutaneous oncology.
Transcenta Holding → AstraZeneca
Transcenta bispecific antibody collaboration with AstraZeneca.
BIOSECURE Risk
UK-domiciled company with clear BIOSECURE status and no current regulatory restrictions
Key Exposures:
- •China manufacturing operations
- •China-based R&D activities
- •Local partnerships with Chinese entities
Mitigation: Company maintains compliance with international regulations and has diversified manufacturing base outside China
BD Intelligence
Therapeutic Areas:
Recent Deals: Highly active in both in-licensing and out-licensing across multiple therapeutic areas with deals typically ranging from hundreds of millions to multi-billion dollar transactions
Approach: Requires C-suite level engagement with well-developed value propositions; focus on differentiated assets in core therapeutic areas
Red Flags
- ⚠Limited visibility into key personnel for BD engagement
- ⚠Highly competitive environment for deal-making
- ⚠Potential future regulatory changes affecting China operations
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 10
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.